Our round-up of biotech financings is led this week by Braveheart Bio, a San Francisco biotech that has launched with $185 million, a lead drug for hypertrophic cardiomyopathy (HCM), and Biogen CEO ...

Braveheart ends with William Wallace shouting “Freedom!” before his execution, turning his death into the movie’s final act of resistance. Directed by Mel Gibson, the 1995 historical epic stars Gibson ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. One of the most controversial movies of 2026 has now hit streaming, a recent addition to the ...

Sam Barsanti has written about pop-culture for 10 years, and his work has appeared at The A.V. Club, Primetimer, IGN, and Collider. He has also contributed to the popular daily Hustle newsletter, ...

Mercy opens in IMAX and 3D theaters on January 23. The screenlife genre gets a buggy update in Timur Bekmambetov’s Mercy, a rapid-action thriller in which a man accused of murder must prove his ...

"Minority Report" but dumb, this screenlife thriller about a cop who has 90 minutes to prove himself innocent of murder to an AI judge isn't terrible, but you can tell everyone's putting half effort ...

Bristol Myers Squibb currently has the only drug approved specifically for treating obstructive hypertrophic cardiomyopathy, a debilitating disorder that can progress to heart failure. But safety ...

With $185 million in series A funding and an army of experienced leaders in its ranks, Braveheart Bio is setting off to joust with big names in an emerging heart disease drug arena. Backed by ...

Board to include Chris Viehbacher as Chair, with investor syndicate led by Andreessen Horowitz, Forbion, and OrbiMed with participation from Enavate Sciences (a platform of Patient Square Capital) and ...

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...